Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CNTX vs SGMT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SGMT Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 4–1 Matrix Metrics)

SGMT Overall Winner 6-Pillar Tally: CNTX 1 – 3 SGMT (2 Tie) Matrix Metrics: CNTX 1 – 4 SGMT

As of Nov 20, 2026, Sagimet Biosciences Inc. Series A (SGMT) is the stronger overall head-to-head candidate over Context Therapeutics Inc. (CNTX) in the Tradestie Institutional Equity Comparison Engine, winning 4–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). CNTX carries a Unified Composite Score of 46.6/100 (HOLD) at $0.16 (N/M Forward P/E, 0.0% operating margin), whereas SGMT carries 44.6/100 (HOLD) at $9.08 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While CNTX currently prints a higher short-term Unified Composite Score (46.6/100 HOLD vs. SGMT 44.6/100 HOLD), SGMT captures the overall institutional head-to-head verdict (4–1 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: CNTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.6); meanwhile SGMT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CNTX vs SGMT
CNTX NASDAQ
Context Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$0.16
-5.1% 1D
Market Cap $15.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.82β · 98% Vol
Unified Composite Score
46.6 / 100 HOLD
Tech 33.0 Fund 58.0 Flow 50.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -25.9%), weak momentum, RSI 32
RSI-14: 31.6 · SMA20: $0.19 · SMA50: $0.26
SGMT NASDAQ Head-to-Head Winner
Sagimet Biosciences Inc. Series A Common Stock
Pharmaceutical Preparations
$9.08
-5.61% 1D
Market Cap $692.0M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.04β · 80% Vol
Unified Composite Score
44.6 / 100 HOLD
Tech 22.0 Fund 48.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.9%), weak momentum, RSI 42
RSI-14: 42.3 · SMA20: $10.14 · SMA50: $9.77

6-Pillar Scorecard Institutional Category Breakdown (CNTX 1 – 3 SGMT)

Columns: Metric · CNTX · SGMT
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale SGMT
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $15.5M $692.0M
3. Profitability & Quality SGMT
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -84.3% -29.5%
4. Balance Sheet & Cash Flow CNTX
Cash Generation (TTM) -$35M -$44M
Cash Flow Margin N/A N/A
Net Cash / Leverage $54M Net Cash $109M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SGMT
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 489.4% (82nd %ile)
Put/Call OI Skew N/A 0.10x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CNTX (1) vs SGMT (4)
Institutional Metric CNTX SGMT Criterion Row Edge
Market Capitalization
Scale
$15.5M $692.0M Larger Scale SGMT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-84.3% -29.5% Higher ROE SGMT
52-Week Range Position
Momentum
0% ($0–$4) 66% ($4–$11) Stronger Trend SGMT
Beta / 30D Volatility
Risk Regime
0.82β · 98% Vol 2.04β · 80% Vol Lower Realized Risk SGMT
Unified Institutional Score
Composite Signal
46.6 / 100 (HOLD) 44.6 / 100 (HOLD) Higher Composite CNTX
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$35M ($54M Net Cash) -$44M ($109M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SGMT +23.35 pp
CNTX: -32.09% · SGMT: -8.74%
3M Horizon SGMT +54.55 pp
CNTX: -65.62% · SGMT: -11.07%
6M Horizon SGMT +121.92 pp
CNTX: -93.85% · SGMT: +28.07%
1Y Horizon SGMT +101.99 pp
CNTX: -86.32% · SGMT: +15.67%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CNTX vs SGMT. Trailing 12-month operating profitability (CNTX 0.0% vs SGMT 0.0%) and valuation multiples (CNTX N/M vs SGMT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CNTX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-84.3% · N/M
SGMT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-29.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CNTX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CNTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SGMT CONSOLIDATION
144d in phase · OBV NEUTRAL
Current IV 489.4%
IV Percentile 82nd %ile
Put/Call OI Skew 0.10x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SGMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CNTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SGMT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $692.0M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CNTX vs SGMT Key Questions & Quantitative Answers

As of Nov 20, 2026, Sagimet Biosciences Inc. Series A (SGMT) is the stronger overall head-to-head candidate over Context Therapeutics Inc. (CNTX) in the Tradestie Institutional Equity Comparison Engine, winning 4–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). CNTX carries a Unified Composite Score of 46.6/100 (HOLD) at $0.16 (N/M Forward P/E, 0.0% operating margin), whereas SGMT carries 44.6/100 (HOLD) at $9.08 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While CNTX currently prints a higher short-term Unified Composite Score (46.6/100 HOLD vs. SGMT 44.6/100 HOLD), SGMT captures the overall institutional head-to-head verdict (4–1 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: CNTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.6); meanwhile SGMT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SGMT leads the Growth & Scale pillar: CNTX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with SGMT at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CNTX generates N/A in USD-normalized revenue versus N/A for SGMT. In operating R&D and SG&A reinvestment, CNTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SGMT.

CNTX and SGMT trade at balanced relative valuation multiples. CNTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas SGMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CNTX (-84.3% ROE) versus SGMT (-29.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CNTX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.82β · 98% Vol realized risk). By comparison, SGMT carries 489.4% implied volatility (82nd %ile, Extreme (>80th %ile)), a 0.10x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (2.04β · 80% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.